Effect of octreotide on adenoma size

In 20 previously untreated acromegalic patients with macroadenomas, short-acting octreotide was administered for 24 weeks and then long-acting octreotide for another 24 weeks to 10 patients.

Data from: Bevan, JS, Atkin, SL, Atkinson, AB, et al. J Clin Endocrinol Metab 2002; 87:4554.

Graphic 65053 Version 1.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟